We are in a severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) pandemic, causing coronavirus disease (COVID-19). SARS-CoV-2 is an enveloped RNA virus with cell entry facilitated by spike (S) protein that has a cleavage site at the S1--S2 boundary and other structural proteins such as membrane (M), envelope (E), and nucleocapsid (N) proteins \[[@CR1]\]. Currently, there are two lineages of SARS-CoV-2 virus infecting humans, with similar virulence and clinical outcomes, derived from a common ancestor that originated in December 2019 in Wuhan \[[@CR1], [@CR2]\]. Most patients who recover from SARS-CoV-2 illness will develop antibodies and memory lymphocytes against these proteins, which gives them immunity \[[@CR3]\]. In this editorial, we discuss the biological, operational, and methodological questions that arise when designing a randomised controlled trial (RCT) of convalescent plasma in COVID-19.

What is convalescent plasma therapy? {#Sec1}
====================================

Convalescent plasma refers to acellular plasma fraction of blood, containing antibodies against SARS-CoV-2 antigens, with virus neutralisation properties, collected from patients who have recovered from SARS-CoV-2 infections. Passive immunisation with ABO blood group-compatible convalescent plasma will reduce viral burden as neutralising antibodies will binding to the viral spike protein to either prevent interaction with angiotensin-converting enzyme-2 receptor or block the conformational changes in spike protein preventing fusion to host cell membrane and provide immunomodulation.

What do we know thus far about convalescent plasma therapy in COVID-19 illness? {#Sec2}
===============================================================================

Since the recent Cochrane review that highlighted very low-certainty evidence on the effectiveness and safety of convalescent plasma in COVID-19 patients \[[@CR4]\], Joyner and colleagues have reported safety results from a compassionate use convalescent plasma therapy programme in 5000 adults with COVID-19. They highlight that convalescent plasma is a safe treatment with an overall serious adverse event rate of \< 1% (*n* = 36 events), with TACO occuring in 7 patients, TRALI in 11 patients, and allergic transfusion reaction in 3 patients \[[@CR5]\]. To date, one RCT has been published. This open-label trial stopped early after recruiting 103 of a planned 200 patients sample size were enrolled. The stoppage was due to low patient recruitment, as the pandemic abated in China, and importantly not for safety reasons \[[@CR6]\]. The participants had either severe (respiratory distress and/or hypoxemia) or life-threatening (shock, organ failure, or requiring mechanical ventilation) COVID-19 illness. The intervention, ABO-compatible convalescent plasma at a dose of 4 to 13 ml/kg of recipient body weight, and with an S-RBD-specific IgG titre of at least 1:640. The primary outcome was time to clinical improvement within 28 days, defined as patient discharged alive or reduction of 2 points on a 6-point disease severity scale. The overall trial result was no statistically significant improvement in time to clinical improvement within 28 days between convalescent plasma with standard of care versus standard of care alone. However, any inference from this trial is limited by it\'s early termination.

Why do we need more RCTs of convalescent plasma? {#Sec3}
================================================

The risks of administering plasma screened for common blood-borne pathogens are small, but include allergy/anaphylaxis, transfusion-related acute lung injury (TRALI), and transfusion-associated circulatory overload (TACO) \[[@CR7]\]. TRALI and TACO are relevant as many COVID-19 patients have incipient respiratory failure that may worsen with convalescent plasma transfusion-related volume loading. Another specific concern with this intervention is antibody-dependent enhancement (ADE). In SARS-1 coronaviruses, ADE occurs by S protein neutralising antibodies enhancing viral entry into cells though fragment-crystallisable (Fc) receptor expressing cells such as monocytes \[[@CR8]\]. This has been shown to worsen lung injury in SARS-1 patients \[[@CR9]\]. Non-randomised clinical use (compassionate) will not provide evidence of efficacy, which is an important consideration, as passive immunotherapy was ineffective in severe influenza A \[[@CR10]\], and Ebola \[[@CR11]\]. The impact of these harms would be difficult to identify outside a well-conducted RCT that collects adverse event data in a standardised way, whilst answering the efficacy question.

Can we rapidly provide convalescent plasma with neutralising antibodies during a pandemic? {#Sec4}
==========================================================================================

Convalescent plasma can be collected safely from individuals who have recovered from laboratory-confirmed SARS-CoV-2 infection, as neutralising antibody responses begin by 14 days and continue to increase over the next few weeks. Currently, it is uncertain how long these antibodies persist, but in other coronavirus infections, neutralising antibodies may persist at high titres for at least 3 months before declining \[[@CR12]\]. Therefore, collection of plasma around 28 days after recovery will provide an effective product with high titres of neutralising antibodies.

However, neither the method to assess viral neutralisation ability of convalescent plasma prior to administration nor the minimum titre of neutralising antibody that is required for treating critically ill patients with COVID-19 is known. There are two methods to assess viral neutralisation ability---pseudotype and live-virus assays. Pseudotype assays using harmless viruses that express the coronavirus spike protein, the target of neutralising antibodies, are a safer, easier, and more sensitive method for detecting neutralising antibody than live-virus assays that assess neutralisation of invasion of tissue culture cells by live virus \[[@CR13]\]. The titres of antibody dose vary between studies, from 400 ml of ABO-compatible convalescent plasma with neutralising antibody titre \> 1:40 \[[@CR14]\] to single 200 ml dose of inactivated convalescent plasma with neutralising antibody titre \> 1:640 \[[@CR15]\].

What are the key design issues to consider in RCTs of convalescent plasma? {#Sec5}
==========================================================================

Current trials include *participants* with a range of COVID-19 illness spectrum, the *intervention* (convalescent plasma different timing, different doses, and need for molecular evidence of viral infection) and *comparators* are different, ranging from standard of care to use of regular plasma for blinding that adds transfusion-related risks in comparator population, and *outcomes* differ between trials. It is conceivable that the treatment effect of convalescent plasma may differ by illness severity, by dose in terms of volume, concentration of neutralisation antibody, and the risk of ADE along with other adverse events during COVID-19 illness (Table [1](#Tab1){ref-type="table"}) \[[@CR4]\]. Table 1Ongoing randomised controlled trials of convalescent plasma in COVID-19 illness assessed using the PICO framework. These RCTs were identified in a recent Cochrane review by Valk et al. \[[@CR4]\]. *Participants*: We report the setting (severely ill/critically ill versus general wards). In high-risk non-ventilated patients (high inspired oxygen, and/or non-invasive ventilation), this could reduce the need for mechanical ventilation. In ventilated patients, this may translate into improved mortality and reduced length of critical care stay. *Intervention*: For intervention, we report the description of convalescent plasma volume and titres if highlighted. In SARS-1 patients, convalescent plasma improved outcomes when administered within 14 days of illness onset and in those without detectable antibodies against coronavirus at the time of infusion. Only four studies use a predetermined neutralising titre cutoff with convalescent plasma. *Comparator*: We highlight whether the ordinary plasma or standard of care was chosen. In five RCTs, the comparator is ordinary plasma transfusion, which may enhance blinding but comes with risks of blood product. When summarising the ongoing current trials, it is unlikely that an efficacy signal would be generated from many of these trials due their methodological limitations (such as small sample size) and biological limitations (such as lack of pre-defined cutoff for neutralising antibody titres). For outcome, we list only the primary outcome for the trial. We also highlight the proposed sample size in the trial.Trial ID \[country\]ParticipantsInterventionComparatorOutcome*N*ChiCTR2000029757 \[China\]Severely ill/critically illVolume = NRStandard of care2-point improvement in clinical symptoms in a 6-point scale200Titres = NRChiCTR2000030010 \[China\]Severely ill adults less than 70 yearsVolume = NROrdinary plasma2-point improvement in clinical symptoms in a 6-point scale100Titres = NRChiCTR2000030179 \[China\]Severely ill adults less than 66 yearsVolume = NRStandard of careCure rate100Titres = NRMortalityChiCTR2000030627 \[China\]Severely ill/critically illVolume = NRStandard of careTemperature control30Titres = NRChiCTR2000030702 \[China\]Hospitalised patientsVolume = NRStandard of careTime to clinical recovery after randomisation50Titres = NRChiCTR2000030929 \[China\]Severely ill adults less than 70 yearsVolume = NROrdinary plasma2-point improvement in clinical symptoms in a 6-point scale60Titres = NREUCTR2020-001310-38 \[Germany\]Severely ill/critically ill adults less than 75 yearsVolume = up to 960 mlStandard of careComposite endpoint:- Survival and no longer fulfilling criteria of severe COVID-19 within 21 days after randomisation120Titres = NRIRCT20200310046736N1 \[Iran\]Adult (20 to 45 years)Volume = 800 mlStandard of careN/A45Titres = NRIRCT20200404046948N1 \[Iran\]Severely ill/critically ill adults less than 70 yearsVolume = up to 500 mlStandard of care2-point improvement in clinical symptoms at 14 days60Titres = NRIRCT20200409047007N1 \[Iran\]Critically ill adults 50--75 years with Pao2/FIO2 ratio \< 300; normal IgA level and within 7 days of admissionVolume = up to 500 mlStandard of care1-month mortality35Titres = NRIRCT20200413047056N1 \[Iran\]Severely ill/critically ill adults less than 50 yearsVolume = up to 400 mlStandard of care or intravenous immunoglobulinNR15(1:1:1) 3-arm studyTitres = NRNCT04332835 \[Columbia\]Hospitalised adults less than 60 yearsVolume = up to 500 mlHydroxychloroquineChange in viral load60Titres = NRChange in antibody titresCoadministration of hydroxychloroquineNCT04333251 \[USA\]Hospitalised adultsVolume = 2 dosesStandard of careReduction in oxygen and ventilation support115Titres = \> 1:64NCT04342182 \[Netherlands\]Hospitalised adultsVolume = up to 300 mlStandard of careMortality426Titres = NRNCT04344535 \[USA\]Hospitalised adultsVolume = up to 550 mlStandard plasmaVentilator-free days up to day 28500Titres = \> 1:320NCT04345289 \[Denmark\]Hospitalised adults with pneumoniaVolume = 600 mlMultiple interventions; adaptive platform trialComposite endpoint of all-cause mortality or need of invasive mechanical ventilation up to 28 days1500Titres = NR1:1:1:1:1:1NCT04345523 \[Spain\]Hospitalised adults with pneumoniaVolume = 800 mlStandard of careWHO ordinal scale278Titres = NRNCT04345991 \[France\]Mild severity as described in the WHO scale, within 8 daysVolume = 800 mlStandard of careSurvival without needs of ventilator utilisation or use of immunomodulatory drugs at 14 days120Titres = NRNCT04346446 \[India\]Severely ill/critically ill adults less than 65 yearsVolume = up to 600 mlStandard of careProportion of patients remaining free of mechanical ventilation at 7 days40Titres = NRNCT04348656 \[Canada\]Hospitalised adults receiving supplemental oxygenVolume = up to 500 mlStandard of careIntubation or hospital mortality within 30 days1200Titres = NRNCT04355767 \[USA\]Adults requiring emergency department evaluationVolume = up to 600 mlStandard plasmaTime to disease progression at 15 days206Titres = \> 1:80NCT04356534 \[Bahrain\]Adults \> 21 years with severely ill with radiological evidence of pneumoniaVolume = up to 600 mlStandard of careRequirement for invasive ventilation40Titres = \> 1:80NCT02735707 \[Multinational\]Severely ill/critically ill adultsVolume = up to 600 mlMultiple interventions; adaptive platform trialDays alive and outside of ICU at 21 days7100 platformTitres = \> 1:64

In summary, there is a clear biological framework for considering convalescent plasma as a potential intervention in COVID-19 illness. However, we need high-quality randomised controlled trials prior to using convalescent plasma as standard care in SARS-CoV-2 infections.
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